Francois Brisebois
Stock Analyst at Oppenheimer
(2.02)
# 2,897
Out of 4,732 analysts
85
Total ratings
36.9%
Success rate
-6.48%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $7.16 | +179.52% | 4 | Dec 17, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $63 → $65 | $46.52 | +39.72% | 6 | Nov 14, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $12.69 | +120.65% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $7.75 | +287.10% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $70.54 | +131.07% | 4 | Oct 31, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Outperform | $56 → $59 | $39.05 | +51.09% | 5 | Oct 30, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $14.13 | +289.24% | 5 | Sep 3, 2024 | |
| KALA KALA BIO | Reiterates: Outperform | $15 | $7.25 | +106.90% | 2 | Aug 19, 2024 | |
| DMAC DiaMedica Therapeutics | Reiterates: Outperform | $6 | $5.71 | +5.08% | 5 | Aug 16, 2024 | |
| ACHV Achieve Life Sciences | Reiterates: Outperform | $11 | $3.09 | +255.99% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $15.16 | -7.65% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $15 | $2.93 | +411.95% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.33 | +477.37% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $29.92 | +117.25% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $4.84 | +106.61% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.85 | +488.30% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $9.13 | +1,564.84% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $17.64 | +104.08% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $1.97 | +103.56% | 3 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.81 | +7,325.74% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $90 | $0.19 | +46,435.68% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 | $0.53 | +843.40% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8.5 | $3.10 | +174.19% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $6.42 | +71.34% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $1.96 | +818.37% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $3.49 | +1,332.66% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $2.90 | +111,624.14% | 1 | Feb 4, 2020 |
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $7.16
Upside: +179.52%
Tarsus Pharmaceuticals
Nov 14, 2024
Maintains: Outperform
Price Target: $63 → $65
Current: $46.52
Upside: +39.72%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $12.69
Upside: +120.65%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $7.75
Upside: +287.10%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $70.54
Upside: +131.07%
Harmony Biosciences Holdings
Oct 30, 2024
Reiterates: Outperform
Price Target: $56 → $59
Current: $39.05
Upside: +51.09%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $14.13
Upside: +289.24%
KALA BIO
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $7.25
Upside: +106.90%
DiaMedica Therapeutics
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $5.71
Upside: +5.08%
Achieve Life Sciences
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.09
Upside: +255.99%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $15.16
Upside: -7.65%
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $2.93
Upside: +411.95%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $4.33
Upside: +477.37%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $29.92
Upside: +117.25%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $4.84
Upside: +106.61%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.85
Upside: +488.30%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $9.13
Upside: +1,564.84%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $17.64
Upside: +104.08%
Apr 4, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $1.97
Upside: +103.56%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.81
Upside: +7,325.74%
Feb 6, 2023
Maintains: Outperform
Price Target: $120 → $90
Current: $0.19
Upside: +46,435.68%
Oct 3, 2022
Upgrades: Outperform
Price Target: $5
Current: $0.53
Upside: +843.40%
Sep 7, 2022
Initiates: Outperform
Price Target: $8.5
Current: $3.10
Upside: +174.19%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $6.42
Upside: +71.34%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $1.96
Upside: +818.37%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $3.49
Upside: +1,332.66%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $2.90
Upside: +111,624.14%